Skip to main content
Clinical Trials/NCT03958474
NCT03958474
Completed
Early Phase 1

Neurobehavioral Mechanisms of Choice in Opioid Use Disorder

Joshua A. Lile, Ph.D.1 site in 1 country12 target enrollmentAugust 16, 2019

Overview

Phase
Early Phase 1
Intervention
Oxycodone
Conditions
Opioid Use Disorder
Sponsor
Joshua A. Lile, Ph.D.
Enrollment
12
Locations
1
Primary Endpoint
Gambling task
Status
Completed
Last Updated
6 months ago

Overview

Brief Summary

The objective of this protocol is to use probabilistic reinforcement learning choice tasks and magnetic resonance neuroimaging to demonstrate the impact of problematic opioid use and opioid withdrawal on dynamic decision-making and reveal the neurobehavioral and neurobiological processes underlying abnormal task performance. A second objective is to identify an appropriate dose of intravenous remifentanil for subsequent studies in physically dependent individuals with opioid use disorder.

Registry
clinicaltrials.gov
Start Date
August 16, 2019
End Date
July 10, 2025
Last Updated
6 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Joshua A. Lile, Ph.D.
Responsible Party
Sponsor Investigator
Principal Investigator

Joshua A. Lile, Ph.D.

Professor

University of Kentucky

Eligibility Criteria

Inclusion Criteria

  • Must meet moderate/severe criteria for moderate/severe opioid use disorder, report recent prescription or illicit opioid use, and be opioid dependent, as evidenced by either a urine sample positive for recent opioid use or being in frank withdrawal during screening.
  • Female subjects must be using an effective form of birth control (e.g., birth control pills, surgical sterilization, IUD, cervical cap with a spermicide, or abstinence).
  • Able to speak and read English
  • Subjects who are interested in completing the remifentanil dose-ranging session must report a history of intravenous opioid use and a baseline O2 saturation of 95% or greater.

Exclusion Criteria

  • History of, or current, clinically significant physical disease (e.g., respiratory disease \[asthma, COPD, sleep apnea\], impaired cardiovascular functioning, seizure disorder or CNS tumors) or current or past history of psychiatric disorder that would limit compliance in the studies, other than substance use disorder.
  • Meet diagnostic criteria for psychoactive substance use disorder for substances other than opioids (OUD subjects only) or nicotine that would require detoxification (i.e., alcohol, benzodiazepines or barbiturates).
  • Contraindications for MRI scanning (e.g., pacemaker, metal implants, claustrophobia, or any other implanted medical device).
  • Vision or hearing problems that would preclude completion of experimental tasks.
  • At risk for respiratory complications and have predictors of difficult bag mask ventilation (e.g., dentures, very full beard), in case emergency respiratory intervention is needed.
  • Seeking treatment for SUD.
  • Poor venous access (only subjects who will participate in the remifentanil dose-ranging session).

Arms & Interventions

Active treatment followed by placebo treatment

Participants complete a gambling task during oxycodone administration and then complete the same gambling task during placebo administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.

Intervention: Oxycodone

Active treatment followed by placebo treatment

Participants complete a gambling task during oxycodone administration and then complete the same gambling task during placebo administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.

Intervention: Remifentanil

Placebo treatment followed by active treatment

Participants complete a gambling task during placebo administration and then complete the same gambling task during oxycodone administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.

Intervention: Oxycodone

Placebo treatment followed by active treatment

Participants complete a gambling task during placebo administration and then complete the same gambling task during oxycodone administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.

Intervention: Remifentanil

Outcomes

Primary Outcomes

Gambling task

Time Frame: Change in monetary rewards earned on a gambling task as a function of the intervention will be assessed by administering this task once per session across two sessions during a 9-day inpatient enrollment in each subject

The number of monetary rewards earned on a gambling task, in which two options signaled by distinct cues are presented on a computer screen and choosing either could result in the delivery of money, but the reinforcement probabilities of the options differ, and change during the task.

Study Sites (1)

Loading locations...

Similar Trials